Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

Synthesis of 13 C6 -labeled, dual-target inhibitor of cannabinoid-1 receptor (CB1 R) and inducible nitric oxide synthase (iNOS).

Iyer MR, Cinar R, Coffey NJ, Kunos G.

J Labelled Comp Radiopharm. 2018 May 23. doi: 10.1002/jlcr.3639. [Epub ahead of print]

PMID:
29790591
2.

Disruption of Renal Arginine Metabolism Promotes Kidney Injury in Hepatorenal Syndrome in Mice.

Varga ZV, Erdelyi K, Paloczi J, Cinar R, Zsengeller ZK, Jourdan T, Matyas C, Nemeth BT, Guillot A, Xiang X, Mehal A, Haskó G, Stillman IE, Rosen S, Gao B, Kunos G, Pacher P.

Hepatology. 2018 Oct;68(4):1519-1533. doi: 10.1002/hep.29915.

PMID:
29631342
3.

Neutrophil-Hepatic Stellate Cell Interactions Promote Fibrosis in Experimental Steatohepatitis.

Zhou Z, Xu MJ, Cai Y, Wang W, Jiang JX, Varga ZV, Feng D, Pacher P, Kunos G, Torok NJ, Gao B.

Cell Mol Gastroenterol Hepatol. 2018 Jan 8;5(3):399-413. doi: 10.1016/j.jcmgh.2018.01.003. eCollection 2018 Mar.

4.

Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity: A Translational Approach.

Valenta I, Varga ZV, Valentine H, Cinar R, Horti A, Mathews WB, Dannals RF, Steele K, Kunos G, Wahl RL, Pomper MG, Wong DF, Pacher P, Schindler TH.

JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 2):320-332. doi: 10.1016/j.jcmg.2017.11.019.

PMID:
29413441
5.

Pro-inflammatory hepatic macrophages generate ROS through NADPH oxidase 2 via endocytosis of monomeric TLR4-MD2 complex.

Kim SY, Jeong JM, Kim SJ, Seo W, Kim MH, Choi WM, Yoo W, Lee JH, Shim YR, Yi HS, Lee YS, Eun HS, Lee BS, Chun K, Kang SJ, Kim SC, Gao B, Kunos G, Kim HM, Jeong WI.

Nat Commun. 2017 Dec 21;8(1):2247. doi: 10.1038/s41467-017-02325-2.

6.

Decreasing CB1 receptor signaling in Kupffer cells improves insulin sensitivity in obese mice.

Jourdan T, Nicoloro SM, Zhou Z, Shen Y, Liu J, Coffey NJ, Cinar R, Godlewski G, Gao B, Aouadi M, Czech MP, Kunos G.

Mol Metab. 2017 Nov;6(11):1517-1528. doi: 10.1016/j.molmet.2017.08.011. Epub 2017 Sep 1.

7.

Cannabinoid-1 receptor deletion in podocytes mitigates both glomerular and tubular dysfunction in a mouse model of diabetic nephropathy.

Jourdan T, Park JK, Varga ZV, Pálóczi J, Coffey NJ, Rosenberg AZ, Godlewski G, Cinar R, Mackie K, Pacher P, Kunos G.

Diabetes Obes Metab. 2018 Mar;20(3):698-708. doi: 10.1111/dom.13150. Epub 2017 Dec 3.

PMID:
29106063
8.

Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling.

Tam J, Szanda G, Drori A, Liu Z, Cinar R, Kashiwaya Y, Reitman ML, Kunos G.

Mol Metab. 2017 Oct;6(10):1113-1125. doi: 10.1016/j.molmet.2017.06.010. Epub 2017 Jun 24.

9.

Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.

Pacher P, Steffens S, Haskó G, Schindler TH, Kunos G.

Nat Rev Cardiol. 2018 Mar;15(3):151-166. doi: 10.1038/nrcardio.2017.130. Epub 2017 Sep 14. Review.

PMID:
28905873
10.

Network analyses identify liver-specific targets for treating liver diseases.

Lee S, Zhang C, Liu Z, Klevstig M, Mukhopadhyay B, Bergentall M, Cinar R, Ståhlman M, Sikanic N, Park JK, Deshmukh S, Harzandi AM, Kuijpers T, Grøtli M, Elsässer SJ, Piening BD, Snyder M, Smith U, Nielsen J, Bäckhed F, Kunos G, Uhlen M, Boren J, Mardinoglu A.

Mol Syst Biol. 2017 Aug 21;13(8):938. doi: 10.15252/msb.20177703.

11.

Hepatic β-arrestin 2 is essential for maintaining euglycemia.

Zhu L, Rossi M, Cui Y, Lee RJ, Sakamoto W, Perry NA, Urs NM, Caron MG, Gurevich VV, Godlewski G, Kunos G, Chen M, Chen W, Wess J.

J Clin Invest. 2017 Aug 1;127(8):2941-2945. doi: 10.1172/JCI92913. Epub 2017 Jun 26.

12.

Synthesis of S-2-((S)-3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamido)-3-(methyl-d3 )butanamide-d5 , octadeuterated JD5037.

Iyer MR, Cinar R, Coffey NJ, Chorvat RJ, Kunos G.

J Labelled Comp Radiopharm. 2017 Aug;60(10):460-465. doi: 10.1002/jlcr.3521. Epub 2017 Aug 2.

13.

Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis.

Cinar R, Gochuico BR, Iyer MR, Jourdan T, Yokoyama T, Park JK, Coffey NJ, Pri-Chen H, Szanda G, Liu Z, Mackie K, Gahl WA, Kunos G.

JCI Insight. 2017 Apr 20;2(8). pii: 92281. doi: 10.1172/jci.insight.92281. [Epub ahead of print]

14.

β-Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and metabolic dysregulation in mice.

Varga ZV, Matyas C, Erdelyi K, Cinar R, Nieri D, Chicca A, Nemeth BT, Paloczi J, Lajtos T, Corey L, Hasko G, Gao B, Kunos G, Gertsch J, Pacher P.

Br J Pharmacol. 2018 Jan;175(2):320-334. doi: 10.1111/bph.13722. Epub 2017 Feb 22.

15.

Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB1R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis.

Iyer MR, Cinar R, Katz A, Gao M, Erdelyi K, Jourdan T, Coffey NJ, Pacher P, Kunos G.

J Med Chem. 2017 Feb 9;60(3):1126-1141. doi: 10.1021/acs.jmedchem.6b01504. Epub 2017 Jan 27.

PMID:
28085283
16.

Developmental Role of Macrophage Cannabinoid-1 Receptor Signaling in Type 2 Diabetes.

Jourdan T, Szanda G, Cinar R, Godlewski G, Holovac DJ, Park JK, Nicoloro S, Shen Y, Liu J, Rosenberg AZ, Liu Z, Czech MP, Kunos G.

Diabetes. 2017 Apr;66(4):994-1007. doi: 10.2337/db16-1199. Epub 2017 Jan 12.

17.

Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis.

Cinar R, Iyer MR, Liu Z, Cao Z, Jourdan T, Erdelyi K, Godlewski G, Szanda G, Liu J, Park JK, Mukhopadhyay B, Rosenberg AZ, Liow JS, Lorenz RG, Pacher P, Innis RB, Kunos G.

JCI Insight. 2016 Jul 21;1(11). pii: e87336.

18.

Cannabinoid receptor signaling regulates liver development and metabolism.

Liu LY, Alexa K, Cortes M, Schatzman-Bone S, Kim AJ, Mukhopadhyay B, Cinar R, Kunos G, North TE, Goessling W.

Development. 2016 Feb 15;143(4):609-22. doi: 10.1242/dev.121731.

19.

Endocannabinoid regulation of β-cell functions: implications for glycaemic control and diabetes.

Jourdan T, Godlewski G, Kunos G.

Diabetes Obes Metab. 2016 Jun;18(6):549-57. doi: 10.1111/dom.12646. Epub 2016 Mar 31. Review.

20.

Stratification of Hepatocellular Carcinoma Patients Based on Acetate Utilization.

Björnson E, Mukhopadhyay B, Asplund A, Pristovsek N, Cinar R, Romeo S, Uhlen M, Kunos G, Nielsen J, Mardinoglu A.

Cell Rep. 2015 Dec 1;13(9):2014-26. doi: 10.1016/j.celrep.2015.10.045. Epub 2015 Nov 19.

21.

Fluoxetine Facilitates Fear Extinction Through Amygdala Endocannabinoids.

Gunduz-Cinar O, Flynn S, Brockway E, Kaugars K, Baldi R, Ramikie TS, Cinar R, Kunos G, Patel S, Holmes A.

Neuropsychopharmacology. 2016 May;41(6):1598-609. doi: 10.1038/npp.2015.318. Epub 2015 Oct 30.

22.

Mice lacking GPR3 receptors display late-onset obese phenotype due to impaired thermogenic function in brown adipose tissue.

Godlewski G, Jourdan T, Szanda G, Tam J, Cinar R, Harvey-White J, Liu J, Mukhopadhyay B, Pacher P, Ming Mo F, Osei-Hyiaman D, Kunos G.

Sci Rep. 2015 Oct 12;5:14953. doi: 10.1038/srep14953.

23.

The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity.

Mukhopadhyay P, Baggelaar M, Erdelyi K, Cao Z, Cinar R, Fezza F, Ignatowska-Janlowska B, Wilkerson J, van Gils N, Hansen T, Ruben M, Soethoudt M, Heitman L, Kunos G, Maccarrone M, Lichtman A, Pacher P, Van der Stelt M.

Br J Pharmacol. 2016 Feb;173(3):446-58. doi: 10.1111/bph.13338. Epub 2016 Jan 15.

24.

Role of the endocannabinoid system in diabetes and diabetic complications.

Gruden G, Barutta F, Kunos G, Pacher P.

Br J Pharmacol. 2016 Apr;173(7):1116-27. doi: 10.1111/bph.13226. Epub 2015 Aug 20. Review.

25.

Biologically active, high levels of interleukin-22 inhibit hepatic gluconeogenesis but do not affect obesity and its metabolic consequences.

Park O, Ki SH, Xu M, Wang H, Feng D, Tam J, Osei-Hyiaman D, Kunos G, Gao B.

Cell Biosci. 2015 May 30;5:25. doi: 10.1186/s13578-015-0015-0. eCollection 2015.

26.

Short- or long-term high-fat diet feeding plus acute ethanol binge synergistically induce acute liver injury in mice: an important role for CXCL1.

Chang B, Xu MJ, Zhou Z, Cai Y, Li M, Wang W, Feng D, Bertola A, Wang H, Kunos G, Gao B.

Hepatology. 2015 Oct;62(4):1070-85. doi: 10.1002/hep.27921. Epub 2015 Jul 3.

27.

Structural Basis of Species-Dependent Differential Affinity of 6-Alkoxy-5-Aryl-3-Pyridinecarboxamide Cannabinoid-1 Receptor Antagonists.

Iyer MR, Cinar R, Liu J, Godlewski G, Szanda G, Puhl H, Ikeda SR, Deschamps J, Lee YS, Steinbach PJ, Kunos G.

Mol Pharmacol. 2015 Aug;88(2):238-44. doi: 10.1124/mol.115.098541. Epub 2015 May 26.

28.

Endocannabinoid signaling at the periphery: 50 years after THC.

Maccarrone M, Bab I, Bíró T, Cabral GA, Dey SK, Di Marzo V, Konje JC, Kunos G, Mechoulam R, Pacher P, Sharkey KA, Zimmer A.

Trends Pharmacol Sci. 2015 May;36(5):277-96. doi: 10.1016/j.tips.2015.02.008. Epub 2015 Mar 18. Review.

29.

Blunted cardiac response to hemorrhage in cirrhotic rats is mediated by local macrophage-released endocannabinoids.

Gaskari SA, Liu H, D'Mello C, Kunos G, Lee SS.

J Hepatol. 2015 Jun;62(6):1272-7. doi: 10.1016/j.jhep.2015.01.021. Epub 2015 Jan 29.

30.

Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms.

Mukhopadhyay B, Schuebel K, Mukhopadhyay P, Cinar R, Godlewski G, Xiong K, Mackie K, Lizak M, Yuan Q, Goldman D, Kunos G.

Hepatology. 2015 May;61(5):1615-26. doi: 10.1002/hep.27686. Epub 2015 Feb 17.

31.

A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome.

Bowles NP, Karatsoreos IN, Li X, Vemuri VK, Wood JA, Li Z, Tamashiro KL, Schwartz GJ, Makriyannis AM, Kunos G, Hillard CJ, McEwen BS, Hill MN.

Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):285-90. doi: 10.1073/pnas.1421420112. Epub 2014 Dec 22.

32.

Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy.

Jourdan T, Szanda G, Rosenberg AZ, Tam J, Earley BJ, Godlewski G, Cinar R, Liu Z, Liu J, Ju C, Pacher P, Kunos G.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5420-8. doi: 10.1073/pnas.1419901111. Epub 2014 Nov 24.

33.
34.

Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.

Tam J, Godlewski G, Earley BJ, Zhou L, Jourdan T, Szanda G, Cinar R, Kunos G.

Am J Physiol Endocrinol Metab. 2014 Feb 15;306(4):E457-68. doi: 10.1152/ajpendo.00489.2013. Epub 2013 Dec 31.

35.

Monounsaturated fatty acids generated via stearoyl CoA desaturase-1 are endogenous inhibitors of fatty acid amide hydrolase.

Liu J, Cinar R, Xiong K, Godlewski G, Jourdan T, Lin Y, Ntambi JM, Kunos G.

Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18832-7. doi: 10.1073/pnas.1309469110. Epub 2013 Nov 4.

36.

The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release.

Kola B, Wittman G, Bodnár I, Amin F, Lim CT, Oláh M, Christ-Crain M, Lolli F, van Thuijl H, Leontiou CA, Füzesi T, Dalino P, Isidori AM, Harvey-White J, Kunos G, Nagy GM, Grossman AB, Fekete C, Korbonits M.

FASEB J. 2013 Dec;27(12):5112-21. doi: 10.1096/fj.13-232918. Epub 2013 Aug 27.

37.

Chronic alcohol produces neuroadaptations to prime dorsal striatal learning.

DePoy L, Daut R, Brigman JL, MacPherson K, Crowley N, Gunduz-Cinar O, Pickens CL, Cinar R, Saksida LM, Kunos G, Lovinger DM, Bussey TJ, Camp MC, Holmes A.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14783-8. doi: 10.1073/pnas.1308198110. Epub 2013 Aug 19.

38.

Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes.

Jourdan T, Godlewski G, Cinar R, Bertola A, Szanda G, Liu J, Tam J, Han T, Mukhopadhyay B, Skarulis MC, Ju C, Aouadi M, Czech MP, Kunos G.

Nat Med. 2013 Sep;19(9):1132-40. doi: 10.1038/nm.3265. Epub 2013 Aug 18.

39.

Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides.

Cinar R, Godlewski G, Liu J, Tam J, Jourdan T, Mukhopadhyay B, Harvey-White J, Kunos G.

Hepatology. 2014 Jan;59(1):143-53. doi: 10.1002/hep.26606. Epub 2013 Nov 18.

40.

Modulating the endocannabinoid system in human health and disease--successes and failures.

Pacher P, Kunos G.

FEBS J. 2013 May;280(9):1918-43. doi: 10.1111/febs.12260. Epub 2013 Apr 22. Review.

41.

Metabolic effects of chronic cannabis smoking.

Muniyappa R, Sable S, Ouwerkerk R, Mari A, Gharib AM, Walter M, Courville A, Hall G, Chen KY, Volkow ND, Kunos G, Huestis MA, Skarulis MC.

Diabetes Care. 2013 Aug;36(8):2415-22. doi: 10.2337/dc12-2303. Epub 2013 Mar 25.

42.

Circulating anandamide and blood pressure in patients with obstructive sleep apnea.

Engeli S, Blüher M, Jumpertz R, Wiesner T, Wirtz H, Bosse-Henck A, Stumvoll M, Batkai S, Pacher P, Harvey-White J, Kunos G, Jordan J.

J Hypertens. 2012 Dec;30(12):2345-51. doi: 10.1097/HJH.0b013e3283591595.

PMID:
23032139
43.

Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance.

Tam J, Cinar R, Liu J, Godlewski G, Wesley D, Jourdan T, Szanda G, Mukhopadhyay B, Chedester L, Liow JS, Innis RB, Cheng K, Rice KC, Deschamps JR, Chorvat RJ, McElroy JF, Kunos G.

Cell Metab. 2012 Aug 8;16(2):167-79. doi: 10.1016/j.cmet.2012.07.002. Epub 2012 Jul 26.

44.

Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity.

Gunduz-Cinar O, MacPherson KP, Cinar R, Gamble-George J, Sugden K, Williams B, Godlewski G, Ramikie TS, Gorka AX, Alapafuja SO, Nikas SP, Makriyannis A, Poulton R, Patel S, Hariri AR, Caspi A, Moffitt TE, Kunos G, Holmes A.

Mol Psychiatry. 2013 Jul;18(7):813-23. doi: 10.1038/mp.2012.72. Epub 2012 Jun 12.

45.

Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice.

Liu J, Zhou L, Xiong K, Godlewski G, Mukhopadhyay B, Tam J, Yin S, Gao P, Shan X, Pickel J, Bataller R, O'Hare J, Scherer T, Buettner C, Kunos G.

Gastroenterology. 2012 May;142(5):1218-1228.e1. doi: 10.1053/j.gastro.2012.01.032. Epub 2012 Jan 31.

46.

Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice.

Bashashati M, Storr MA, Nikas SP, Wood JT, Godlewski G, Liu J, Ho W, Keenan CM, Zhang H, Alapafuja SO, Cravatt BF, Lutz B, Mackie K, Kunos G, Patel KD, Makriyannis A, Davison JS, Sharkey KA.

Br J Pharmacol. 2012 Mar;165(5):1556-71. doi: 10.1111/j.1476-5381.2011.01644.x.

47.

The endocannabinoid 2-arachidonoylglycerol mediates D1 and D2 receptor cooperative enhancement of rat nucleus accumbens core neuron firing.

Seif T, Makriyannis A, Kunos G, Bonci A, Hopf FW.

Neuroscience. 2011 Oct 13;193:21-33. doi: 10.1016/j.neuroscience.2011.07.055. Epub 2011 Jul 27.

48.

The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications.

Kunos G, Tam J.

Br J Pharmacol. 2011 Aug;163(7):1423-31. doi: 10.1111/j.1476-5381.2011.01352.x. Review.

49.

Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver.

Mukhopadhyay B, Cinar R, Yin S, Liu J, Tam J, Godlewski G, Harvey-White J, Mordi I, Cravatt BF, Lotersztajn S, Gao B, Yuan Q, Schuebel K, Goldman D, Kunos G.

Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6323-8. doi: 10.1073/pnas.1017689108. Epub 2011 Mar 7.

50.

Endocannabinoids in liver disease.

Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G.

Hepatology. 2011 Jan;53(1):346-55. doi: 10.1002/hep.24077. Review.

Supplemental Content

Support Center